Investigating melanoma in children, adolescents, and young adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to explore melanoma, a type of skin cancer, specifically in children, adolescents, and young adults, referred to as CAYA patients. Due to the rarity of melanoma in individuals under 30, the study seeks to gather critical information to improve diagnosis and treatment options for this demographic. It will involve standardization of tissue samples, histopathological analysis, and advanced imaging techniques to characterize melanoma samples. The data collected will also contribute to a Pan-European online platform for collaboration among healthcare professionals dealing with complex melanoma cases.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* adolescent and childhood patients (\< 20 years) or young adults (\< 30 years)
* histologically confirmed diagnosis of melanoma or intermediate/ambiguous melanocytic neoplasm (i.e., melanocytomas, SAMPUS, IAMPUS and MELTUMP according to WHO classification)

Exclusion criteria:

* adult patients (\> 30 years of age)
* patients without histologically confirmed diagnosis of melanoma or intermediate/ambiguous melanocytic neoplasm

Where it's running

• University of Florence
  Florence, Italy, Italy Recruiting

Study contacts

• Principal investigator: Massi Daniela — University of Florence (UNIFI)
• Study coordinator: Daniela Massi Professor
• Email: daniela.massi@unifi.it
• Phone: 3925536585

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalized adapted exercise program for advanced melanoma

  This will try a personalized adapted physical activity program for adults with advanced melanoma who are receiving immunotherapy or targeted therapy.

  Recruiting University Hospital, Rouen · Rouen · NCT07031830

• Melanoma in adults aged 18 to 39.

  This project will collect clinical, dermoscopic, pathology, and molecular data to see how common melanoma is and what risk factors and skin features it has in people aged 18–39.

  Recruiting Ente Ospedaliero Ospedali Galliera · Genoa, Liguria · NCT06994208

• Combining toripalimab and endostatin for treating stage II melanoma

  This study is testing if combining a new cancer drug with another treatment can help people with stage II melanoma live longer without their cancer coming back after surgery.

  Recruiting at 4 sites Phase 2 Fudan University · Shanghai, Shanghai Municipality and 3 other locations · NCT06965231

• Measuring metabolites in melanoma patients using advanced techniques

  This study is testing if analyzing blood and other body fluids from melanoma patients can help spot the disease earlier and track any changes in their condition.

  Recruiting Technische Universität Dresden · Dresden, Saxony · NCT06765850

• PD-L1-targeted PET probe to map PD-L1 in solid tumors

  A PET tracer called 18F-F-PDL1-3 is being tested to see if it can detect PD-L1 expression in primary and metastatic tumors to help guide personalized treatment.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing · NCT07848243

• ctDNA-guided stopping of immune therapy in advanced melanoma

  This study tests whether stopping immune checkpoint inhibitor therapy after 12 months is safe for patients with advanced melanoma who have undetectable ctDNA and disease control.

  Recruiting Rutgers, The State University of New Jersey · New Brunswick, New Jersey · NCT07830225

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.